Compare
Abbott Laboratories vs Insulet (ABT vs PODD)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Abbott Laboratories (ABT) returned -11.7% and Insulet (PODD) -53.4%; so far this year the figures are -12.3% and -48.5%.
Abbott Laboratories is the larger company by market value, about 18.7 times the size of Insulet.
On trailing earnings, ABT trades at 40.9 times and PODD at 23.9 times.
Revenue grew +10.0% at ABT and +26.5% at PODD over the last year.
ABT yields 2.29%. PODD pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABT | PODD | |
|---|---|---|
| Price | $109.93 | $146.51 |
| 1-day | -3.23% | -6.16% |
| YTD | -12.26% | -48.46% |
| 1 year | -11.73% | -53.41% |
| 3 years | +15.70% | +6.38% |
| Market cap | $190.4B | $10.2B |
| P/E | 40.9 | 23.9 |
| P/S | 3.95 | 3.19 |
| P/B | 3.73 | 6.44 |
| Revenue growth | +10.00% | +26.50% |
| EPS growth | -66.20% | +78.20% |
| Gross margin % | 56.9 | 71.9 |
| Net margin % | 9.7 | 13.4 |
| ROE % | 9.2 | 27.2 |
| Debt / equity | 0.61 | 0.61 |
| FCF yield % | 3.5 | 2.6 |
| Dividend yield % | 2.29 | — |
| Beta | 0.06 | 0.41 |
| RSI (14) | 58.5 | 49.6 |
| Technical rating |